Drug Trial Radar · NCT01140321
Efficacy and Safety of Neridronate (Nerixia®)to Treat Osteoporosis in Patients With TM and TI
Last checked: Nov 19, 2026Latest source record: Feb 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Jan 2004
Primary completion
May 2010
Study completion May 2010
Sponsor
- Lead sponsor
- Ente Ospedaliero Ospedali GallieraAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ospedale Maggiore Policlinico Mangiagalli e Regina Elena; Ospedale "Perrino" Brindisi; Reggio Calabria; Azienda Ospedaliera Villa Sofia; Azienda Ospedaliera V. Cervello; Università di Ferrara; University of Campania Luigi Vanvitelli
- First posted
- Jun 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Italian Multicentric randomized, open-label therapeutic trial evaluating the efficacy and safety of Neridronate in the treatment of Osteoporosis in patients with Thalassemia Major and Severe Thalassemia Intermedia. Efficacy and safety of the drug will be evaluated measuring at every visit this parameters: * haematological: Haemochrome * blood chemistry: creatinine, BUN, AST, ALT, Ca, P, proteins electrophoresis, total proteins. The prevalence of ectopic calcification and pseudoxantoma elasticum (PXE)-like syndrome and their follow-up will be evaluated at the beginning of the study vs 24 months through physical examination, abdominal echography and fundus oculi examination. During the trial other known risks factors for osteoporosis will be recorded, including prevalence and incidence of bone fractures and, if executed, Polimorphisms COLIA1. At the beginning of the study and at months 12 and 24 morphometry DXA will be performed to evaluate of the presence of bone deformities. Furthermore data regarding QOL and symptom pain will be evaluated trough administration of scale SF-36. At 12 months an intratrial analisis will be performed on efficacy and safety parameters in order to introduce possible amendments to the study design and to decide the prosecution of the trial During the trial all adverse events will be recorded
Conditions
- Osteoporosis
- Thalassemia Major
- Thalassemia Intermedia
Interventions
NeridronateDrug
Neridronate is an aminobisphosfonate of third generation that has been proved in several clinical trials to have the ability to inhibit osteoclast-mediated bone resorption and it is generally well tollerated also at high doses. Thanks to these properties it has been used in the treatment of several bone disorders such as Paget's disease and Osteogenesis Imperfecta. Neridronate, given intravenously or orally (tablets), reduces both the levels of bone alcaline phosphatase and of the other markers of bone resorption activity. Recently it has been approved by the Italian Ministry of Health for the commercialization with the indication "Osteogenesis Imperfecta".
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Divisione di Ematologia, Ospedale "Perrino"
Brindisi, Italy
Dipartimento di Medicina Clinica e Sperimentale, Sezione di Pediatria, Università di Ferrara
Ferrara, Italy
Centro della Microcitemia e delle Anemie Congenite - Ematologia E.O. Ospedali Galliera
Genova, Italy
SC Geriatria E.O. Ospedali Galliera
Genova, Italy
Centro Anemie Congenite, Ospedale Maggiore Policlinico, IRCCS, University of Milan
Milan, Italy
U.O. "Ematologia II con Talassemia" A.O. " V. Cervello
Palermo, Italy
U.O. Pediatria II, A.O. "Villa Sofia"
Palermo, Italy
Centro Microcitemia, A.O. B.M.M.
Reggio Calabria, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.